Browsing: News

Press Release – Roche’s Tecentriq® SC (atezolizumab) becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Singapore, reducing treatment time to a few minutes

By 0
Roche announced today that Tecentriq® SC (atezolizumab) has been approved by the Singapore Health Sciences Authority (HSA) for all indications in which the intravenous (IV) formulation of Tecentriq has been previously approved, including certain types of lung, breast and liver cancer.4 Tecentriq SC is Roche’s fourth subcutaneous cancer therapy,5-7 and the world’s first injectable anti-PD-(L)1 cancer immunotherapy.

Log In or Register as a healthcare professional to read the full article.

NUH Trauma Centre Enhances Safety for Vulnerable Groups

By 0

The National University Hospital (NUH) has launched the National University Centre for Trauma. This centre focuses on comprehensive trauma care and outreach to vulnerable groups, including children, older adults, and migrant workers. The initiative aims to enhance safety and prevent trauma across Singapore.

Unregistered Pilgrims’ Deaths: A Health Crisis during the Hajj

By 0

Following the deaths of at least 1,300 people at this year’s hajj, the health of pilgrims in Saudi Arabia has become a critical issue. Witnesses and experts say a combination of scorching temperatures and difficulties with crowd control made the sacred event disorienting and dangerous. These pilgrims lack access to essential facilities like air-conditioned buses and tents. Consequently, they must endure long walks under the scorching sun without adequate protection. This situation highlights significant health risks associated with unregistered Hajj participation.